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Background: Integrated health care delivery systems devote considerable resources to developing quality
improvement (QI) interventions. Clinics serving vulnerable populations rarely have the resources for such development
but might benefit greatly from implementing approaches shown to be effective in other settings. Little trial-based
research has assessed the feasibility and impact of such cross-setting translation and implementation in community
health centers (CHCs). We hypothesized that it would be feasible to implement successful QI interventions from
integrated care settings in CHCs and would positively impact the CHCs.
Methods: We adapted Kaiser Permanente’s successful intervention, which targets guideline-based cardioprotective
prescribing for patients with diabetes mellitus (DM), through an iterative, stakeholder-driven process. We then
conducted a cluster-randomized pragmatic trial in 11 CHCs in a staggered process with six “early” CHCs implementing
the intervention one year before five “‘late” CHCs. We measured monthly rates of patients with DM currently prescribed
angiotensin converting enzyme (ACE)-inhibitors/statins, if clinically indicated. Through segmented regression analysis,
we evaluated the intervention’s effects in June 2011–May 2013. Participants included ~6500 adult CHC patients with
DM who were indicated for statins/ACE-inhibitors per national guidelines.
Results: Implementation of the intervention in the CHCs was feasible, with setting-specific adaptations. One year
post-implementation, in the early clinics, there were estimated relative increases in guideline-concordant prescribing of
37.6 % (95 % confidence interval (CI); 29.0–46.2 %) among patients indicated for both ACE-inhibitors and statins and
38.7 % (95 % CI; 23.2–54.2 %) among patients indicated for statins. No such increases were seen in the late (control)
clinics in that period.
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Conclusions: To our knowledge, this was the first clinical trial testing the translation and implementation of a
successful QI initiative from a private, integrated care setting into CHCs. This proved feasible and had significant impact
but required considerable adaptation and implementation support. These results suggest the feasibility of adapting
diverse strategies developed in integrated care settings for implementation in under-resourced clinics, with important
implications for efficiently improving care quality in such settings.
ClinicalTrials.gov: NCT02299791.
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Integrated health care delivery systems such as Kaiser
Permanente (KP) invest considerable resources in devel-
oping and implementing quality improvement (QI) ini-
tiatives and strategies for internal use. The community
health centers (CHCs) constituting the health care safety
net in the USA provide high-quality care to vulnerable
(and growing) populations [1–3]; however, like most
clinics serving low-income populations in the USA and
internationally, these clinics have few resources for de-
veloping QI strategies comparable to those at large, inte-
grated care systems. Patients and providers in clinics
serving vulnerable populations would likely benefit from
adopting approaches proven effective in better-resourced
systems, but the feasibility and effectiveness of such
cross-system adaptation and implementation have rarely
been tested. Thus, we sought to determine whether and
how interventions that work in private, integrated care
settings can be translated into clinics with fewer re-
sources, using CHCs in the USA as an example of such
clinics.
We hypothesized that cross-setting translation is feas-
ible and that adapting and implementing proven QI
approaches could improve the care provided by under-
resourced clinics without requiring them to develop native
initiatives. We anticipated that this would involve substan-
tially adapting potentially “translatable“ practices and in-
terventions, due to the differences between private care
settings and public clinics in terms of patient needs and
vulnerability and system resources. We tested these
hypotheses by adapting a diabetes QI initiative proven ef-
fective in KP, implementing it in 11 CHCs in a staggered-
implementation, cluster-randomized pragmatic trial and
measuring post-implementation impact in the CHCs.
To our knowledge, this is the first randomized trial of
the feasibility and impact of translating a QI initiative
developed and proven effective in an integrated care set-
ting, for implementation in under-resourced clinics. Our
overarching goal was to identify and resolve barriers to
effectively implementing a successful, privately devel-
oped QI program into CHCs, to pave the way for future
cross-setting dissemination of evidence-based programsinto our nation’s safety net clinics and under-resourced
clinics internationally. We report the results of this im-
plementation trial.
The A.L.L. Initiative intervention
Kaiser Permanente’s “A.L.L. Initiative” (Aspirin, Lova-
statin (any statin), Lisinopril (any angiotensin converting
enzyme-inhibitor (ACE) or angiotensin receptor blocker
(ARB)); hereafter called “ALL”) is a system- and clinic-
level QI intervention. Implemented throughout KP in
2003, ALL was designed to increase rates of patients
with diabetes who are appropriately prescribed cardio-
protective aspirin, statins, and ACE/ARBs. (Because the
evidence for aspirin changed, we did not target it here.)
At KP, ALL used electronic health record (EHR)-based
tools coupled with top-down strategies to incentivize
provider uptake. Its overarching strategies were to facili-
tate providers: (1) identifying patients with diabetes who
were indicated for the ALL medications but not taking
an indicated medication and (2) prescribing these medi-
cations. ALL was highly successful in KP: an internal
study estimated a >60 % reduction in cardiovascular dis-
ease (CVD) events among targeted adults taking the
ALL medications for 1–2 years [4, 5]. We selected ALL
as a “test case” for studying cross-setting translational
implementation based on its strong underlying evidence
[4, 6–23], its alignment with national treatment guide-
lines, its impressive impact at KP, the simplicity of its
strategies, and preliminary evidence that it could be
adapted for the safety net [6].
Adapting the intervention for implementation in the
study sites
To adapt ALL for implementation in CHCs, we under-
went an iterative, year-long process involving re-
searchers, electronic health record (EHR) programmers,
and CHC staff and providers, as previously described
[24]. In brief, while the overall intervention aims and
EHR tool functions remained the same as in KP’s imple-
mentation, each intervention component was custom-
ized to fit the CHCs’ needs and EHR capabilities. Each
study CHC used the combination of components that
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mentation strategies [25] were likewise adapted to
emphasize practice facilitation [26–30], due to the
CHCs’ different organizational structures and re-
sources [31]. Table 1 summarizes the intervention
components in both settings and how they were
translated for implementation in the study CHCs. De-
tails on the components of the implemented interven-
tion were previously reported [24].
Methods
Setting and data sources
The 11 study CHCs are ambulatory primary care clinics
managed by three Federally Qualified Health CenterTable 1 Summary of ALL initiative when implemented in KP and as
At KP
Overarching strategies Make it easier for providers to: (1
medication(s), but have no activ
medications
Target population
Population “indicated” for ACE/ARBs and/
or statins
Patients with diabetes at high ris
comorbid CVD)
Intervention components: Tools to expedite identifying patients indicated fo
Automated EHR point-of-care alerts “fire”
at patient encounters if ALL medications
indicated but not prescribed
Alerts added to existing, interna
Support Tool” which identifies m
based on EHR data1;2
Data registries enable searching provider/
clinic panel for patients for whom ALL
medications indicated but not prescribed
Integrated into existing panel to
patients (i) on the day of a clinic
“huddle,” and (ii) in targeted out
addition to other care gaps
Intervention components: Tools to expedite prescribing
Order sets in EHR to make prescribing
easier
Pre-programmed to expedite “o
for any indicated ALL medicatio
Intervention components: Tools to enhance patient adherence
Patient education materials EHR shortcuts that expedite pro
generate informational text abou
in after-visit summaries
Outreach to patients missing a
prescription
Nurse, pharmacy case managers
up appointment to get prescript
Compliance tracking Nurse, pharmacy case managers
remind them to refill their presc
Intervention components: Strategies to encourage provider uptake
Communicate expectations related to
intervention uptake
Top-down practice change direc
Orient staff to the evidence underlying
the intervention
Champions presented at departm
Ongoing implementation support Regional clinician champions res
multiple QI initiatives, including
Performance tracking—providers Monthly performance reports, po
tied to staff incentives(FQHC) systems in the Portland, Oregon metropolitan
area. All are members of OCHIN, Inc., a non-profit
organization that provides health information technology
to safety net clinics [32–34]. The study CHCs vary in size
and organizational structure: one is operated by a large
academic medical center, though it is not located at that
center; six by a county health department in urban loca-
tions; and four by a non-profit organization primarily
serving suburban, Spanish-speaking populations. These
clinics share a single EHR which is managed centrally at
OCHIN, including regular data validation. EHR data for
these analyses were extracted at OCHIN. Results from our
extensive process evaluation will be reported in future
manuscripts. [35]adapted for CHCs
As adapted for and implemented in the
study CHCs
) identify patients with diabetes who are indicated for an ALL
e prescription for an indicated medication, and (2) prescribe these
k of CVD (55-75, or Any adult patients with diabetes (18-75)
r but not prescribed ALL medication(s)
lly built “Patient
yriad “care gaps”
Alerts in the form of “Best Practice Alert” built into
existing EHR functions; no other care gaps
identified by this alert
ol; used to identify
visit, at the team
reach efforts, in
Built as stand-alone ALL-specific rosters; provide








Similar EHR shortcuts; exam room poster about the
ALL medications in English, Spanish, Russian;
handouts to enhance adherence to prescribed
medications in English, Spanish, Russian
call patients to set
ion
At clinic discretion, used ALL registries to facilitate
outreach to diabetic patients overdue for a visit
call patients to
riptions
Not part of the CHCs’ intervention due to limited
outreach capacity
tives Presented as recommendations; staff input/
feedback solicited
ent meetings Practice facilitators and/or clinician champions




ALL-specific practice facilitators (clinic employees)
provide on-the-ground support; clinician cham-
pions at each organization; research staff provides
additional support
sted publicly and Monthly reports made available; emphasis, timing,
and method of distribution varied by organization
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In our staggered, cluster-randomized implementation strat-
egy, six study clinics were randomized to implement the
intervention in June 2011 (early implementation), and five
1 year later (late implementation). Cluster randomization
was used because this is a clinic-level intervention with
clinic-level outcomes. Randomization was matched on size
of the clinics’ patient population and the FQHC system op-
erating the clinic. The intervention’s effect was evaluated
using an interrupted time-series design, analyzed with seg-
mented regression models with calendar months as the
unit of analysis [36].
Main outcomes and measurements
Our outcome of interest was the proportion of patients
with diabetes who were indicated for cardioprotective
medication(s) (denominator) and had an “active” pre-
scription for the indicated medication(s) (numerator),
calculated monthly. We measured two clinic-level pre-
scribing rates: (1) the proportion of patients indicated
for ACE/ARB and statin who had an active prescription
for both, and (2) the proportion indicated for statin only
who had an active statin prescription.
Rate denominator
Each month’s rate denominator included clinic patients
with diabetes who had a clinic encounter (in person or
by telephone) in the last year and were indicated for one
or both medications per current national care guidelines
[37]. Patients were considered indicated for (a) an ACE/
ARB and a statin, if age 55–75 or age 18–54 with
comorbid CVD; or for (b) a statin only, if age 18–54
with last low-density lipoprotein (LDL) >100. Patients
currently pregnant or breastfeeding were excluded. Pa-
tients with a history of anaphylactic reaction to either
medication were excluded from analyses involving that
medication.
Rate numerator
Patients were considered to have an active prescription
for an indicated medication class if they were prescribed
that medication in the last year. Since the intervention
targets provider prescribing rates, we consider this defin-
ition acceptable because it reflects the prescription data
available to providers in the EHR.
Statistical analyses
The early implementation effects on the two prescribing
rates of interest were estimated using segmented regres-
sion models with two groups—the early implementation
clinics were modeled as the intervention group and the
late implementation clinics as the control group. We
used data from 24 monthly intervals: 12 in the pre-
intervention period (June 2010–May 2011) and 12 in thepost-intervention period (June 2011–May 2012). Models
included a constant term, a term to model the slope of
the pre-intervention linear trend, a variable to indicate
study group (intervention vs. control), terms to estimate
change in level from pre- to post-intervention and
change in slope of the trend, and interaction terms
(group by pre-intervention trend, group by change in
level, and group by change in trend) to test for signifi-
cantly greater improvement in prescribing rates in the
early implementation clinics, compared to the controls.
The change in level provides an estimate of the immedi-
ate effect of the intervention; the change in trend, an es-
timate of its effect across time post-implementation.
Analyses of late implementation effects involved the
late implementation clinics only, with level and trend of
the pre-intervention period serving as controls for the
post-intervention period. These analyses included 36
monthly intervals: 24 in the pre-intervention period
(June 2010–May 2012) and 12 in the post-intervention
period (June 2012–May 2013). Models contained a con-
stant term, a term for the slope of the pre-intervention
linear trend, and terms estimating pre/post-intervention
changes in level and trend of outcome rates.
Preliminary qualitative analyses indicated that pro-
viders modified ALL medication prescribing based on
patient age and gender. (Because of the teratogenic risks,
some providers were wary of prescribing to younger fe-
males, and others were reluctant to prescribe statins to
younger patients in general; details of these qualitative
results pending in future papers). To account for poten-
tial differences in prescribing rates based on distribution
of these factors across clinic groups, we adjusted all
models for gender (percentage of denominator who were
female at each time point), age (percentage of denomin-
ator age 18–39 on the first day of each month), and their
interaction. All regression models also included a first-
order autoregressive term to control for serial autocor-
relation [36]. All analyses reflect tests of statistical
significance with a two-sided α of 0.05 and were con-
ducted using SAS Enterprise Guide 6.1 (PROC AUTO-




For illustrative purposes, Table 2 presents patient char-
acteristics by clinic group in June 2010 (baseline), June
2011 (beginning of early implementation), and May 2012
(beginning of late implementation). At baseline, 1152 pa-
tients with diabetes were indicated for both a statin and
an ACE/ARB in the early implementation clinics and
879 in the late implementation clinics (Table 2). Most
were aged 55–75. About 47 % had prescriptions for both
indicated medications. There were 494 patients indicated
Table 2 Patient demographics by clinic group at selected time points in study period
June 2010 June 2011 May 2012
Early clinics Late clinics Early clinics Late clinics Early clinics Late clinics
Indicated for ACE/ARB and statin
Patients with DM, no. 1152 879 1446 1179 1599 1436
% with CVD, age 18–39 years 0.2 0.1 0.3 0.2 0.4 0.4
% with CVD, age 40–54 years 7.9 4.8 6.3 5.0 6.8 4.9
% age 55–75 years 91.9 95.1 93.4 94.8 92.9 94.7
Gender
% Female 61.0 61.9 60.4 58.8 58.3 58.0
Medication
% with active prescription for ACE/ARB, statin 47.9 47.1 49.9 45.4 62.3 47.0
Indicated for statin only
Patients with DM, no. 494 424 607 624 761 720
% without CVD, age 18–39 years, last LDL >=100 34.2 30.9 32.8 32.2 30.6 30.7
% without CVD, age 40–54 years, last LDL >=100 65.8 69.1 67.2 67.8 69.4 69.3
Gender
% Female 63.4 57.3 61.8 58.3 61.4 57.9
Medication
% with active prescription for statin 55.7 52.1 51.6 47.8 63.7 51.8
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424 in the late implementation clinics, about 2/3 of
whom were aged 40–54. About 56 % of early implemen-
tation clinic patients had an active statin prescription as
indicated, as did about 52 % of late implementation
clinic patients. All 11 clinics stayed in the study through-
out the study period.Impact of the early implementation
The effect of the intervention’s early implementation on
guideline-concordant prescribing rates is shown in Fig. 1
and Table 3. Among patients indicated for both an ACE/
ARB and statin (Fig. 1a), the pre-implementation trend
in prescribing rates did not differ between the two
groups (p = 0.744). The change in level, reflecting impact
at the first time point post-implementation, was not sig-
nificantly different between the groups (p = 0.685), but
the groups did differ in the change in slope pre- versus
post-implementation; the early implementation clinics
had a significantly greater increase in this prescribing
rate over time, compared to the late implementation
clinics (p < 0.0001).
Baseline trend lines were used to estimate an expected
prescribing rate in the early implementation clinics after
1 year (by May 2012), if the intervention had not oc-
curred. Using these methods, without the intervention,
the prescribing rate in the early intervention clinics
12 months after implementation was estimated to be
45.8 %. With the intervention, the estimated prescribingrate was 63.0 %, representing a relative increase of
37.6 % (95 % CI; 29.0–46.2 %). The relative increase in
the late implementation clinics in the same time period
was estimated to be 8.4 % (95 % CI; −0.3–17.1 %).
Among patients indicated for statins only (Fig. 1b), pre-
scribing trends declined slightly during the pre-
intervention period and were not significantly different
for the clinic groups in the pre-implementation period
(p = 0.673). There was a significantly greater increase in
prescribing rates immediately post-implementation in the
early clinics, compared to the late clinics (p = 0.040). The
slope of prescribing rates increased post-implementation,
although the change in trend from pre- to post-
implementation was not significantly different in early
versus late clinics (p = 0.131). The estimated rate of statin
prescribing in the early clinics without the intervention
was 48.4 %. With the intervention, it was 67.2 %, a relative
increase of 38.7 % (95 % CI; 23.2–54.2 %). The relative in-
crease in the late clinics in the same time period was esti-
mated to be 19.8 % (95 % CI; 2.7–36.9 %).Impact of the late implementation
Guideline-concordant prescribing rates pre- and post- the
late clinics’ implementation are displayed in Fig. 2. Among
patients indicated for both ACE/ARB and statin (Fig. 2a),
prescribing rates were flat in the pre-intervention period
(slope = 0.0081, p = 0.9331). The slope of prescribing rates
significantly increased post-implementation (change from
pre- to post- implementation, 0.6552; p < 0.0001). Here,
AB
Fig. 1 Effect of the early implementation of the ALL intervention. Time series of prescribing rates by month. a Statin and ACE among patients
indicated for both drugs; b statins among patients indicated for statins only. Dashed vertical line indicates when early clinic implementation
began (June 2011)
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ing rate for ACE/ARB and statin would be 49.5 % at the
end of the study period; with the intervention, the esti-
mated prescribing rate was 57.2 %, a relative increase of
15.5 % (95 % CI; 9.0–22.1 %).
A similar response to the intervention was observed
among patients indicated for statins only (Fig. 2b).
The pre-intervention prescribing rate for statins was
flat (slope = 0.009, p = 0.9377) and improved signifi-
cantly following the intervention (slope change, 0.8246;p = 0.0011). If the intervention had not occurred, the
statin prescribing rate at the end of the observation
period was estimated to be 53.0 %. With the interven-
tion, the estimated prescribing rate was 62.2 %, a rela-
tive increase of 17.3 % (95 % CI; 2.4–32.2 %).
Discussion
There is a known need to expedite the dissemination of
effective interventions across all care settings [38–40].
Doing so would facilitate the spread of proven interventions
Table 3 Results of segmented regression analyses, early implementation effects (Controls = late implementation clinics)
Estimate Standard Error p value
Percent actively prescribed statin and ACE/ARB, among patients indicated for both
Difference in slope of the trend between control and intervention groups prior to the intervention 0.040 0.1208 0.744
Difference between control and intervention groups in change in level following the intervention 0.398 0.9742 0.685
Difference between control and intervention groups in change in slope of the trend from pre- to
post-intervention
1.102 0.1706 <0.001
Percent actively prescribed statins, among patients indicated for a statin only
Difference in slope of the trend between control and intervention groups prior to the intervention 0.103 0.241 0.673
Difference between control and intervention groups in change in level following the intervention 4.225 1.987 0.040
Difference between control and intervention groups in change in slope of the trend from pre- to
post-intervention
0.491 0.318 0.131
Full models included a constant term, a term to model the pre-intervention linear trend slope, a variable for study group (intervention vs. control), terms to esti-
mate change in level from pre- to post-intervention and change in slope of the trend, interaction terms (group by pre-intervention trend, group by change in level
and group by change in trend), percent female, percent aged 18–39, gender by age interaction, and a first-order autoregressive parameter
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systems to develop their own. Although this dissemination
would be particularly useful to under-resourced clinics
serving vulnerable populations in the USA and elsewhere,
such clinics have historically been under-studied in dissem-
ination and implementation science [41]. Instead, most pre-
vious QI efforts in CHCs and similar clinics were internally
developed (a few exceptions cited here), and most cross-
setting implementation research has focused on translation
across similar care settings [28, 30, 41–48].
We believe this was the first clinical trial of the feasi-
bility and impact of translating a QI intervention devel-
oped and shown effective in a private, integrated care
setting, for implementation in under-resourced clinics.
We showed that such translation and implementation is
feasible but may require substantial adaptation to meet
local needs and structures. In brief, we adapted the
intervention components for implementation in the
study clinics, as directed by an iterative process involv-
ing clinic staff. KP’s key strategies—making it easier to
identify patients “missing” an indicated medication, and
to prescribe that medication—remained the same; we
adapted the specifics of how these strategies were im-
plemented (including adapting the tools) and sup-
ported [24, 31].
Lessons learned about adapting QI interventions for
implementation in under-resourced clinics include: (i)
Consider the strategies used to support uptake of an
adapted intervention [25]. Here, KP used top-down di-
rectives coupled with financial incentives; the CHCs
used on-site facilitation. Though not a difference in the
intervention itself, this could influence its uptake. (ii)
Clinic cultures and leadership styles (e.g., degree to
which top-down directives are issued and followed) can
influence adoption of practice change initiatives, and
should be considered when adapting such interventions.
(iii) Though difficult and time-consuming, collaborative
decision-making by clinic leaders (related to how toadapt the intervention) may be essential to eventual up-
take. (iv) Ensure that the intervention aligns with the
clinic’s standards of care; if possible, integrate it into the
official standard of care. (v) Consider that low-income
and otherwise vulnerable patients can face barriers to
acting on medical recommendations—barriers not easily
addressed through alerts and panel tools—and adapt as
possible to address these barriers.
The demonstrated feasibility of effectively implement-
ing a proven intervention in CHCs has important impli-
cations for safety net clinics in the USA and internationally.
As such clinics rarely have the resources to develop “home-
grown” interventions, implementing those shown effective
elsewhere could yield important efficiencies in efforts to im-
prove health care quality and outcomes. Such cross-setting
translation should be considered a realistic means of help-
ing lower-income clinics implement cutting-edge, effective
QI strategies. Although implementing strategies from other
settings requires adaptation to meet the clinics’ needs, it is
likely more efficient than these clinics developing their own
“from scratch”—an efficiency that could support dissemin-
ation of effective strategies across CHCs and similar care
settings.
Comparing the impact of implementing ALL in the
study CHCs versus KP is difficult for several reasons
(some parallel study limitations, below). KP targeted pa-
tients with diabetes aged ≥55 and/or those with coron-
ary artery disease at high risk for CVD, whereas in the
study CHCs, the intervention targeted all adult patients
with diabetes (an adaptation the CHCs requested). KP
was able to measure uptake of ALL using dispense and
refill data; we could only access prescribing data from
OCHIN’s EHR, which until recently lacked medication
dispensing data. Thus, this study would consider a pa-
tient’s care as appropriate even if the prescribed medi-
cation was never dispensed—a method of assessing
guideline concordance that was less stringent by neces-
sity. (Such primary non-adherence occurs in about 5 %
Fig. 2 Effect of the late implementation of the ALL intervention. Time series of prescribing rates by month in late clinics only. a Statin and ACE
among patients indicated for both drugs; b Statins only among patients indicated for statins only. Dashed vertical line indicates when late clinic
implementation began (June 2012)
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among uninsured CHC patients—preliminary qualita-
tive analyses suggest that even small co-payments for
prescriptions created an important barrier). KP started
with considerably lower rates of concordance with tar-
geted outcomes and at a time when there was less evi-
dence supporting the medications’ effectiveness. When
KP implemented ALL in 2003, about 33 % of their target
population were appropriately taking the ALL medica-
tions; this rose to 52 % by 2005, a 58 % relative increase
[4]. In the study CHCs, at baseline, about 48 % of pa-
tients indicated for an ACE/ARB and a statin wereprescribed both. One year post-intervention, this in-
creased to 62 % in the early clinics and 57 % in the late
clinics. While we had thus limited ability to directly
compare the impact of implementing ALL in KP versus
the study CHCs, our results nevertheless show signifi-
cant improvement in the CHCs.
The relative increases in guideline-concordant pre-
scribing reported here range from 16–39 %. While these
improvements are significant, the overall rates of appro-
priate prescribing ranged from 57–67 % by the end of
the reporting period, meaning that 33–43 % of patients
still did not receive prescriptions that were considered
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field’s current technical capacity and understanding of
how to build effective EHR-based QI/decision support
interventions. From a technical perspective, patients
may be incorrectly identified as indicated for a given
medication for myriad reasons that are potentially diffi-
cult to capture in an EHR-based algorithm, including:
patient seeks pregnancy, complex concurrent medical
conditions, potential medication interactions, and medi-
cation(s) prescribed elsewhere/entered in the chart in a
way that does not trigger the algorithm. This illustrates
the challenges inherent to striking a balance between
false positives and false negatives when creating decision
support algorithms in complex populations. This may
also suggest that the implemented intervention was
more successful than it appears, because some patients
in the rate denominators could not be given the target
medications. We plan to conduct further research on
optimizing decision support tools adapted for safety net
clinics.
Limitations
(1) We defined an active prescription as one issued in
the last year, because the EHR contained data on medi-
cation prescriptions but not dispenses. We felt this ac-
ceptably reflected provider behaviors and information
available to providers in the EHR, in the context of an
intervention targeting provider prescribing behaviors.
However, it does not describe rates of patients actually
taking the medications; further research is needed to ad-
dress this. (2) Some patients and providers likely
“crossed over” from early to late clinics during the study
year, even though the intervention components were
only activated for staff at specified clinics per our
randomization strategy; this is because a small percent-
age of CHC staff served patients at both early and late
clinics, and the point-of-care alerts were seen by early
CHC providers regardless of where they provided care.
Though unavoidable in this pragmatic trial, any such
contamination would underestimate intervention im-
pacts, creating bias towards the null. (3) The technology
and QI resources available needed to support such an
intervention may not be available to other clinics, par-
ticularly those serving vulnerable populations.
Next steps/future research
This is the first of several planned papers on this study.
We intend, in future manuscripts, to describe how the
intervention’s impact sustained over time, its impact on
health measures (blood pressure, lipid levels), and pa-
tient, provider, and system-level factors associated with
use of the intervention components and implementation
success. We are also developing a guide to implementing
this intervention in CHCs. Our results indicate the needfor research on the most effective methods for support-
ing future intervention implementation in under-
resourced clinics in the USA and internationally and for
improving the design of EHR-based decision support
tools.
Conclusions
This study adds substantially to our understanding of
whether and how QI strategies proven effective in
better-resourced care settings can be translated into
under-resourced clinics. Such translation and implemen-
tation could potentially yield important benefits to
clinics serving low-income populations by helping them
keep up with the care delivery innovations that other
settings develop. Developing strong practices for cross-
setting implementation of effective innovations could
substantially help safety net clinics benefit from tested
interventions and processes and optimize health system
performance [50].
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